{"id":55036,"date":"2026-01-22T01:51:02","date_gmt":"2026-01-21T17:51:02","guid":{"rendered":"https:\/\/flcube.com\/?p=55036"},"modified":"2026-01-22T01:51:03","modified_gmt":"2026-01-21T17:51:03","slug":"biokins-iza-bren-adc-receives-nmpa-filing-acceptance-for-escc-worlds-first-egfrxher3-bispecific","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55036","title":{"rendered":"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific"},"content":{"rendered":"\n<p><strong>Sichuan Biokin Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its market filing for <strong>iza-bren<\/strong>, an <strong>in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC)<\/strong>, for the treatment of <strong>recurrent or metastatic esophageal squamous cell carcinoma (ESCC)<\/strong>, marking the <strong>first EGFR\u00d7HER3 ADC globally<\/strong> to enter market review.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd (688506.SH)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Iza\u2011bren (EGFR\u00d7HER3 bispecific ADC)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Market filing (NDA)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Recurrent or metastatic esophageal squamous cell carcinoma (ESCC)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>14\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>World\u2019s first EGFR\u00d7HER3 bispecific ADC to enter market review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-development\">Drug Profile &amp; Clinical Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Bispecific ADC<\/strong> targeting <strong>EGFR<\/strong> and <strong>HER3<\/strong>, delivering a cytotoxic payload to tumor cells with <strong>dual receptor expression<\/strong><\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Subject to <strong>40+ clinical trials<\/strong> across China and the US for various tumor types<\/li>\n\n\n\n<li><strong>Regulatory Designations:<\/strong><\/li>\n\n\n\n<li><strong>China:<\/strong> <strong>7 Breakthrough Therapy Designations (BTDs)<\/strong> and <strong>2 priority review statuses<\/strong><\/li>\n\n\n\n<li><strong>US:<\/strong> <strong>1 BTD<\/strong> for an undisclosed indication<\/li>\n\n\n\n<li><strong>Awaiting Decision:<\/strong> Locally advanced or metastatic <strong>nasopharyngeal carcinoma<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Breadth:<\/strong> Iza\u2011bren is the <strong>most decorated ADC in China\u2019s pipeline<\/strong> by regulatory accolades<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China ESCC Market<\/th><th>Global ESCC Market<\/th><\/tr><\/thead><tbody><tr><td><strong>New Cases (2026E)<\/strong><\/td><td>320,000<\/td><td>600,000<\/td><\/tr><tr><td><strong>Recurrent\/Metastatic<\/strong><\/td><td>95,000<\/td><td>180,000<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Chemo \u00b1 immunotherapy (PD\u20111 inhibitors)<\/td><td><\/td><\/tr><tr><td><strong>EGFR\u00d7HER3 ADC Penetration<\/strong><\/td><td>0%<\/td><td>0%<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a58.5\u202fbillion<\/td><td>$3.2\u202fbillion<\/td><\/tr><tr><td><strong>Iza\u2011bren Peak Share<\/strong><\/td><td>15%<\/td><td>5%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a51.3\u202fbillion<\/td><td>$160\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADCs:<\/strong> <strong>RC48<\/strong> (RemeGen, HER2 ADC) \u2013 limited to HER2+ subset; <strong>no EGFR\u00d7HER3 competitors<\/strong> in late\u2011stage development<\/li>\n\n\n\n<li><strong>Immunotherapy:<\/strong> <strong>Keytruda + chemo<\/strong> approved for 1L ESCC; <strong>Iza\u2011bren<\/strong> targets <strong>PD\u20111 refractory<\/strong> and <strong>EGFR\/HER3 co\u2011expressing<\/strong> population (estimated 40% of ESCC)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>First bispecific ADC<\/strong> in solid tumors; <strong>dual receptor targeting<\/strong> may overcome resistance to monospecific ADCs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Biokin\u2019s <strong>Chengdu ADC facility<\/strong> (capacity 10,000\u202fL) will produce Iza\u2011bren for China and global trials; <strong>scale\u2011up to 30,000\u202fL<\/strong> planned for 2027<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> <strong>2,500\u2011hospital oncology network<\/strong> established for companion diagnostics (EGFR\/HER3 testing); <strong>NRDL fast\u2011track<\/strong> expected given 7 BTDs<\/li>\n\n\n\n<li><strong>Global Licensing:<\/strong> Biokin plans <strong>ex\u2011China partnerships<\/strong> post\u2011approval; potential <strong>$1.5\u20112.0\u202fbillion licensing deal<\/strong> for US\/EU rights<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Success validates <strong>bispecific ADC platform<\/strong>, supporting <strong>early\u2011stage assets<\/strong> (e.g., iza\u2011bren\u2011002 for gastric cancer)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for Iza\u2011bren. Actual results may differ due to competitive dynamics, clinical trial outcomes, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688506_20260121_L348.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260121_L348.\"><\/object><a id=\"wp-block-file--media-4eeecf84-a643-43a2-a6d0-625b3b2a97d3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688506_20260121_L348.pdf\">688506_20260121_L348<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688506_20260121_L348.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4eeecf84-a643-43a2-a6d0-625b3b2a97d3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,16,38,857],"class_list":["post-55036","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-cancer","tag-market-approval-filings","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its market filing for iza-bren, an in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of recurrent or metastatic esophageal squamous cell carcinoma (ESCC), marking the first EGFR\u00d7HER3 ADC globally to enter market review.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55036\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its market filing for iza-bren, an in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of recurrent or metastatic esophageal squamous cell carcinoma (ESCC), marking the first EGFR\u00d7HER3 ADC globally to enter market review.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55036\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-21T17:51:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-21T17:51:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55036#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55036\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific\",\"datePublished\":\"2026-01-21T17:51:02+00:00\",\"dateModified\":\"2026-01-21T17:51:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55036\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Cancer\",\"Market approval filings\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55036#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55036\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55036\",\"name\":\"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-21T17:51:02+00:00\",\"dateModified\":\"2026-01-21T17:51:03+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its market filing for iza-bren, an in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of recurrent or metastatic esophageal squamous cell carcinoma (ESCC), marking the first EGFR\u00d7HER3 ADC globally to enter market review.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55036#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55036\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55036#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its market filing for iza-bren, an in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of recurrent or metastatic esophageal squamous cell carcinoma (ESCC), marking the first EGFR\u00d7HER3 ADC globally to enter market review.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55036","og_locale":"en_US","og_type":"article","og_title":"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its market filing for iza-bren, an in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of recurrent or metastatic esophageal squamous cell carcinoma (ESCC), marking the first EGFR\u00d7HER3 ADC globally to enter market review.","og_url":"https:\/\/flcube.com\/?p=55036","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-21T17:51:02+00:00","article_modified_time":"2026-01-21T17:51:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55036#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55036"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific","datePublished":"2026-01-21T17:51:02+00:00","dateModified":"2026-01-21T17:51:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55036"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Cancer","Market approval filings","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55036#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55036","url":"https:\/\/flcube.com\/?p=55036","name":"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-21T17:51:02+00:00","dateModified":"2026-01-21T17:51:03+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its market filing for iza-bren, an in\u2011house developed, first\u2011in\u2011class EGFR\u00d7HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of recurrent or metastatic esophageal squamous cell carcinoma (ESCC), marking the first EGFR\u00d7HER3 ADC globally to enter market review.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55036#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55036"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55036#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biokin\u2019s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World\u2019s First EGFR\u00d7HER3 Bispecific"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55036"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55036\/revisions"}],"predecessor-version":[{"id":55040,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55036\/revisions\/55040"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}